Aptevo Sets Sept 22 Vote on 5.58M Warrant Shares and 180K Equity Plan Increase
APVO is trading near its 52-week low of $2.301 (6.1% above the low).
Summary
Aptevo's definitive proxy sets a September 22 vote on 5.58M warrant shares from its $4.5M August financing and a 180K-share equity plan increase. Approval is required under Nasdaq rules and unlocks the full financing; rejection would void the warrants and force repeated shareholder meetings.
Key Events · Financing and Capital Events · APVO
-
Special Meeting Set for Sept 22
Definitive proxy filed for a virtual special meeting on September 22, 2026, with a record date of August 13, 2026, to vote on four proposals including warrant share issuance and equity plan increase.
-
5.58M Warrant Shares Require Approval
Proposal 2 seeks approval for 5,583,150 shares issuable upon exercise of Common Warrants and Inducement Warrants at $4.03 per share, exceeding 19.99% of the 1,801,970 shares outstanding and triggering Nasdaq Listing Rule 5635(d).
-
Rejection Voids Warrants
If shareholders reject Proposal 2, the Inducement Warrants and Common Warrants become worthless and the company must call a new meeting every 60 days until approval is obtained, potentially discouraging future investors.
-
Equity Plan Increase of 180K Shares
Proposal 3 authorizes 180,000 additional shares under the Fifth Amended and Restated 2018 Stock Incentive Plan, supplementing the 152,360 shares remaining available, to fund equity grants through approximately December 31, 2027.
Analysis · APVO · Life Sciences
Aptevo's definitive proxy sets a September 22, 2026 special meeting to approve the issuance of 5,583,150 shares underlying warrants from its August $4.5 million financing, plus 180,000 new equity plan shares. The warrant shares represent more than 19.99% of the 1,801,970 shares outstanding, triggering Nasdaq's shareholder approval requirement. If shareholders reject the proposal, the Inducement Warrants and Common Warrants become worthless and the company must call a new meeting every 60 days until approval is obtained — a costly and distracting cycle for a company already facing going-concern doubts. The $4.03 exercise price is above the current $2.44 share price, meaning the warrants are out-of-the-money today, but approval removes a major overhang and unlocks the full $4.5 million in committed capital.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APVO was trading at $2.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4M. The 52-week trading range was $2.30 to $48.78. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.